Nami Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 2.00 M
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.96 Cr
- Revenue Growth -12.69%
- Profit Growth -41.94%
- Ebitda -41.68%
- Net Worth 12.14%
- Total Assets -9.61%
About Nami Lifesciences
Nami Lifesciences Private Limited (NLPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 August 2016 (Eight years and six months 0 days old ). Its registered office is in Rangareddy, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹5.96 Cr.
Nithish Vardhelli and Pradeep Chinthakuntla serve as directors at the Company.
Company Details
-
Location
Rangareddy, Telangana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24304TG2016PTC111480
-
Company No.
111480
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Aug 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Nami Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nithish Vardhelli
|
Director | 23-Jun-2021 | Current |
|
Pradeep Chinthakuntla
|
Director | 23-Jun-2021 | Current |
Financial Performance of Nami Lifesciences.
Nami Lifesciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.69% decrease. The company also saw a substantial fall in profitability, with a 41.94% decrease in profit. The company's net worth Soared by an impressive increase of 12.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nami Lifesciences?
In 2023, Nami Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹59.61 M
₹0
Charges Breakdown by Lending Institutions
- Others : 5.29 Cr
- Idbi Bank Limited : 0.50 Cr
- Hdfc Bank Limited : 0.17 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Mar 2023 | Others | ₹5.29 Cr | Open |
| 28 Dec 2022 | Hdfc Bank Limited | ₹1.71 M | Open |
| 17 Dec 2018 | Idbi Bank Limited | ₹5.00 M | Open |
How Many Employees Work at Nami Lifesciences?
Unlock and access historical data on people associated with Nami Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nami Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nami Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
